A patient on nebivolol (Bystolic) 5 mg daily has bradycardia (heart rate ~40) and elevated systolic blood pressure (~140 mm Hg); what medication adjustment is recommended?

Discontinue or Reduce Nebivolol and Add a Dihydropyridine Calcium Channel Blocker

The best medication adjustment is to reduce or discontinue nebivolol (Bystolic) and add a dihydropyridine calcium channel blocker (CCB) such as amlodipine to control the elevated blood pressure without worsening bradycardia.

Clinical Reasoning

Your patient presents with two competing problems:

• Symptomatic bradycardia (HR in 40s) - a contraindication to continuing beta-blocker therapy
• Uncontrolled hypertension (SBP ~140s) - requiring additional BP management

Why Beta-Blocker Reduction is Essential

The 2017 ACC/AHA Hypertension Guidelines explicitly state that beta-blockers are not recommended as first-line agents for uncomplicated hypertension unless the patient has ischemic heart disease (IHD) or heart failure 1, 2, 3. The FDA label for Bystolic lists severe bradycardia as a contraindication 4. The 2008 ESC Heart Failure Guidelines specify that sinus bradycardia <50 bpm is a contraindication to beta-blocker therapy 5.

Critical pitfall: Do not abruptly discontinue nebivolol if the patient has coronary artery disease, as this can precipitate acute coronary syndrome 4. Taper over 1-2 weeks when possible.

Optimal Replacement Strategy

Add a dihydropyridine CCB (amlodipine 2.5-10 mg daily or nifedipine LA 30-90 mg daily) as your primary antihypertensive 1, 2, 3. The 2017 ACC/AHA Guidelines recommend thiazide diuretics, long-acting dihydropyridine CCBs, or ARBs as first-line therapy for uncomplicated hypertension 1.

Why dihydropyridine CCBs are ideal here:

• They effectively lower BP without causing bradycardia
• The 2024 ESC Guidelines support CCBs as first-line therapy 6
• They do not share nebivolol's negative chronotropic effects
• Amlodipine has once-daily dosing and proven cardiovascular outcomes

Avoid non-dihydropyridine CCBs (diltiazem, verapamil) as they cause additional bradycardia and heart block, especially problematic in a patient already bradycardic 1, 2, 3.

Specific Medication Adjustment Algorithm

If Patient Has NO Coronary Artery Disease:

1. Stop nebivolol 5 mg immediately
2. Start amlodipine 5 mg daily (or nifedipine LA 30 mg daily)
3. Recheck BP and HR in 2 weeks
4. Titrate amlodipine up to 10 mg if BP remains elevated

If Patient HAS Coronary Artery Disease:

1. Reduce nebivolol to 2.5 mg daily (half the current dose)
2. Add amlodipine 5 mg daily simultaneously
3. After 1 week, reduce nebivolol to 2.5 mg every other day
4. After another week, discontinue nebivolol completely
5. Titrate amlodipine to 10 mg if needed for BP control

Alternative Options if CCB Not Tolerated:

• ACE inhibitor (lisinopril 10-40 mg daily) or ARB (losartan 50-100 mg daily) 1, 2
• Thiazide diuretic (chlorthalidone 12.5-25 mg daily or hydrochlorothiazide 12.5-25 mg daily) 1

Important Caveats

Monitor for pedal edema with dihydropyridine CCBs, which occurs in a dose-dependent manner and is more common in women 1, 2. This is not dangerous but may affect adherence.

Check renal function before initiating ACE inhibitors or ARBs if considering these alternatives, as they can worsen renal function in bilateral renal artery stenosis 1.

Assess for heart failure: If the patient has heart failure with reduced ejection fraction (HFrEF), nebivolol may be indicated despite bradycardia, but the dose should be reduced to 1.25 mg daily and uptitrated slowly 5. However, with HR in the 40s, even this requires extreme caution.

The 2020 Hypertension Canada Guidelines support this approach, recommending thiazide diuretics, long-acting dihydropyridine CCBs, or ARBs as first-line therapy, with beta-blockers reserved for specific comorbidities 7.